Schneider D T, Lemburg P, Sprock I, Heying R, Göbel U, Nürnberger W
Department of Pediatric Hematology and Oncology, Children's Hospital, Heinrich-Heine-University, Medical Center, Düsseldorf, Germany.
Bone Marrow Transplant. 2000 May;25(10):1079-86. doi: 10.1038/sj.bmt.1702403.
Prognostic scoring systems based on physiological parameters have been established in order to predict the outcome of ICU patients. It has been demonstrated that the predictive value of these scores is limited in patients following hematopoietic stem cell transplantation (HSCT). Therefore, we evaluated patients from the Düsseldorf pediatric stem cell transplantation center with regard to predisposing factors and prognostic variables for ICU treatment and outcome. Between January 1989 and December 1998, 180 HSCT have been performed. The clinical, laboratory and HSCT-related parameters such as conditioning treatment, engraftment, GVHD, infections and HSCT toxicity were prospectively recorded and retrospectively analyzed. Established pediatric scoring systems (PRISM, TISS, P-TISS) were applied. Twenty-eight patients required intensive care (16 male, 12 female, median age: 10.9 years (range: 0.4 to 18.9 years), five autologous, 13 allogeneic-related and 10 unrelated transplanted patients). Ventilator-dependent respiratory failure was the most frequent cause of admission to the ICU (n = 23). Fourteen of 28 patients were discharged from ICU, and six of 28 patients achieved a long-term survival (110 to 396 weeks). At admission to the ICU, impaired cardiovascular status, high CRP levels and presence of macroscopic bleeding were each associated with fatal outcome (P < 0.05). The Pediatric Risk of Mortality (PRISM) score was not prognostically significant at the 0.05 level. Long-term survival after discharge from the ICU correlated with HSCT-related parameters such as the type of transplant and severity of GVHD (P = 0.002). By introduction of HSCT related parameters such as severity of GVHD (grade 2: 2 points; grade >2: 4 points), CRP-level (>10 mg/dl: 4 points), and presence of macroscopic bleeding (4 points) into the PRISM score a new oncological PRISM ('O-PRISM') score was established. This score significantly correlated with the risk of mortality in the ICU (P = 0.01). In conclusion, the new O-PRISM score accurately characterizes the clinical situation of children requiring ICU treatment following HSCT. It distinguishes more appropriately between success and failure of ICU treatment following HSCT than the standard prognostic scores. It needs to be evaluated in future prospective studies of critically ill children after HSCT. Bone Marrow Transplantation (2000).
为了预测重症监护病房(ICU)患者的预后,已经建立了基于生理参数的预后评分系统。事实证明,这些评分在造血干细胞移植(HSCT)后的患者中的预测价值有限。因此,我们评估了来自杜塞尔多夫儿科干细胞移植中心的患者,以了解其ICU治疗及预后的易感因素和预后变量。1989年1月至1998年12月期间,共进行了180例HSCT。前瞻性记录并回顾性分析了临床、实验室及与HSCT相关的参数,如预处理治疗、植入、移植物抗宿主病(GVHD)、感染和HSCT毒性。应用了已有的儿科评分系统(PRISM、TISS、P-TISS)。28例患者需要重症监护(16例男性,12例女性,中位年龄:10.9岁(范围:0.4至18.9岁),5例自体移植,13例亲缘异体移植和10例非亲缘异体移植患者)。依赖呼吸机的呼吸衰竭是入住ICU最常见的原因(n = 23)。28例患者中有14例从ICU出院,28例患者中有6例实现长期生存(110至396周)。入住ICU时,心血管状态受损、高CRP水平和存在肉眼可见出血均与死亡结局相关(P < 0.05)。儿科死亡风险(PRISM)评分在0.05水平上无预后意义。从ICU出院后的长期生存与HSCT相关参数如移植类型和GVHD严重程度相关(P = 0.002)。通过将GVHD严重程度(2级:2分;>2级:4分)、CRP水平(>10 mg/dl:4分)和肉眼可见出血(4分)等HSCT相关参数纳入PRISM评分,建立了新的肿瘤学PRISM(“O-PRISM”)评分。该评分与ICU中的死亡风险显著相关(P = 0.01)。总之,新的O-PRISM评分准确地描述了HSCT后需要ICU治疗的儿童的临床情况。与标准预后评分相比,它能更恰当地区分HSCT后ICU治疗的成功与失败。它需要在未来对HSCT后危重症儿童的前瞻性研究中进行评估。《骨髓移植》(2000年)